Moderna: Citigroup cuts to sell from neutral, raises target price to $80 from $60
MRNA•Citigroup cut its rating on Moderna to sell from neutral and raised its target price to $80 from $60.
Related News
Clough Global Dividend and Income Fund pays monthly distribution of $0.0566 a share
GLV•
Erock Inc coverage initiated with buy rating and $24 price target
EROC•
Pyxis Oncology drops on $110 million stock-and-warrants deal
PYXS•
Inflation jumps across euro zone, raising pressure on ECB to hike
TLT•
AGI seeks debenture maturity extension to 2030, proposes coupon step-up to 9%
AGG•